Clinical Trial

A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

This is a multicenter, randomized, study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo. The primary objectives are to evaluate the safety and efficacy of the vaccine compared to placebo.


Principal Investigator Dynio Honrubia, MD
Sponsor National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC)
Type of Trial Interventional